BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2534648)

  • 21. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
    Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
    Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The application of photopheresis in the therapy of cancerous and autoimmune diseases].
    Dall'Amico R; Zacchello G; Heald P
    Recenti Prog Med; 1991 May; 82(5):294-9. PubMed ID: 1887157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained remission of Sézary syndrome.
    Bouwhuis SA; McEvoy MT; Davis MD
    Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photopheresis: a new therapeutic concept.
    Edelson RL
    Yale J Biol Med; 1989; 62(6):565-77. PubMed ID: 2700056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis.
    Lim HW; Harris HR
    Dermatol Surg; 1995 Jul; 21(7):597-9. PubMed ID: 7606369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.
    Lee CH; Mamelak AJ; Vonderheid EC
    Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.
    Miller JD; Kirkland EB; Domingo DS; Scull H; Jekutis B; Dallas M; Cooper KD; Baron ED
    Photodermatol Photoimmunol Photomed; 2007 Oct; 23(5):163-71. PubMed ID: 17803594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
    Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
    Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
    Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
    Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma.
    Med Lett Drugs Ther; 1988 Oct; 30(776):96. PubMed ID: 3050409
    [No Abstract]   [Full Text] [Related]  

  • 34. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.
    Scarisbrick JJ; Taylor P; Holtick U; Makar Y; Douglas K; Berlin G; Juvonen E; Marshall S;
    Br J Dermatol; 2008 Apr; 158(4):659-78. PubMed ID: 18241274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photopheresis therapy for cutaneous T-cell lymphoma.
    Duvic M; Hester JP; Lemak NA
    J Am Acad Dermatol; 1996 Oct; 35(4):573-9. PubMed ID: 8859287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastasizing squamous cell carcinomas in a patient treated with extracorporeal photopheresis for cutaneous T-cell lymphoma.
    Hoetzenecker W; Benedix F; Woelbing F; Yazdi A; Breuninger H; Röcken M; Berneburg M
    Acta Derm Venereol; 2007; 87(5):445-6. PubMed ID: 17721661
    [No Abstract]   [Full Text] [Related]  

  • 37. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis.
    Demierre MF; Ferzli P; Miller D
    Arch Dermatol; 2007 May; 143(5):659-61. PubMed ID: 17515522
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of cutaneous T-cell lymphoma: an update.
    Young JW
    J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
    Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
    J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.